UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 ~~UNDER THE SECURITIES EXCHANGE ACT OF 1934~~

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2018

Commission File Number 001-33042

ROSETTA GENOMICS LTD.

(Translation of registrant’s name into English)

10 Plaut Street, Science Park ~~Rehovot 76706, Israel (Address of Principal Executive Offices)~~

Rehovot 76706, Israel

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-For Form 40-F:

Form 20-F x

Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Rosetta Genomics Ltd.

On April 510, 2018, ~~Rosetta Genomics Ltd~~Mr.~~, issued~~ aKen ~~press~~Berlin ~~release~~notified the ~~urging~~Board ~~shareholders~~of toRosetta ~~vote~~Genomics inLtd. ~~favor~~(the of“Company”) ~~the~~that ~~proposed~~he ~~merger~~is ~~with~~resigning ~~Genoptix,~~as ~~Inc.~~President Aand ~~copy~~CEO of the ~~press~~Company, ~~release~~effective isApril ~~filed~~18, as2018, ~~Exhibit 99.1~~ to ~~this~~pursue ~~Form~~other ~~6-K and incorporated by reference herein~~opportunities.

~~Exhibits~~The information in this Form 6-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Exhibit Number		Description of Exhibit
99.1		Press Release dated April 5, 2018.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ROSETTA GENOMICS LTD.
Date: April 5, 2018	By:	/s/ Ron Kalfus
Date: April 10, 2018	By:	/s/ Ron Kalfus
		Ron Kalfus
		Chief Financial Officer

Filing Compare · Rosetta Genomics Ltd.